Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics, Inc. executive Gregory Russotti reported an automatic sale of shares to cover taxes on vested stock awards. On June 12, 2026, 2,584 shares of common stock were sold in open-market transactions at an average price of $2.232 per share to satisfy tax withholding obligations tied to restricted stock unit vesting. The filing explains these sales were automatic and not at Russotti’s discretion. After the sale, he directly held 512,319 common shares and indirectly held 92,773 shares through the Gregory Russotti 2021 Family Trust.
Century Therapeutics, Inc. senior vice president of finance and operations Douglas Carr reported an automatic sale of common stock tied to tax withholding. On June 12, 2026, he sold 1,654 shares at $2.232 per share in an open-market transaction to cover taxes from restricted stock unit vesting.
These sales were executed automatically and not at his discretion, according to the disclosure. After the transaction, Carr still directly owns 505,094 shares of Century Therapeutics common stock, indicating he retains a substantial equity position in the company.
Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a tax-related share disposition. On the vesting of restricted stock units, the company withheld 13,849 shares of Common Stock at $2.24 per share to satisfy tax withholding obligations. This was not an open-market sale, and Pfeiffenberger continues to hold 3,665,474 shares of Common Stock directly after the transaction.
Century Therapeutics, Inc. Chief Scientific Officer Chad Cowan reported routine share activity related to equity compensation. On June 11, 2026, 358 shares of common stock were withheld at $2.24 per share to cover tax obligations upon the vesting of restricted stock units, which is not an open-market sale. After this tax-withholding disposition, Cowan directly holds 1,175,322 common shares. A separate entry reports 10,697 common shares held indirectly by the Cowan Investment Nominee Trust, for which he disclaims beneficial ownership except to any pecuniary interest.
Century Therapeutics director Alessandro Riva received a grant of stock options as compensation. The Form 4 shows an award of 74,000 stock options, each allowing the purchase of one share of common stock at an exercise price of $2.24 per share.
The options expire on June 11, 2036 and vest on the earlier of June 11, 2027 or the next annual meeting of stockholders, in each case only if Riva continues in service through the vesting date. Following this grant, he holds 74,000 options directly.
Century Therapeutics director Daphne Quimi received a grant of stock options for 74,000 shares of Common Stock. The options have an exercise price of $2.24 per share, expire on June 11, 2036, and vest on the earlier of June 11, 2027, or the next annual stockholder meeting, subject to continued service. Following this grant, Quimi holds 74,000 stock options directly.
Century Therapeutics director Martin Patrick Murphy received a grant of stock options as part of his compensation. He was awarded options covering 74,000 shares of common stock at an exercise price of $2.24 per share, expiring on June 11, 2036.
The option vests on the earlier of June 11, 2027 or the next annual meeting of stockholders, subject to his continued service through the vesting date. Following this grant, he holds options for 74,000 shares directly, with no open-market buying or selling reported in this filing.
Century Therapeutics, Inc. reported that director Lee Han Myung received a grant of stock options covering 74,000 shares of common stock. The options have an exercise price of $2.24 per share and expire on June 11, 2036.
The option award vests on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, in each case only if Lee Han Myung continues to serve through the vesting date. Following this grant, the filing shows holdings of 74,000 stock options directly.
Century Therapeutics director Kimberly Blackwell received a stock option grant for 74,000 shares of common stock. The option has an exercise price of $2.24 per share and expires on June 11, 2036. All 74,000 options vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to her continued service.
Century Therapeutics, Inc. increased the number of authorized shares of its common stock from 300,000,000 to 450,000,000 through a Certificate of Amendment that became effective on June 12, 2026. Stockholders approved this Authorized Shares Amendment at the company’s 2026 Annual Meeting.
At the same meeting, stockholders elected Alessandro Riva, M.D. and Han Lee, Ph.D., M.B.A. as Class II directors, each to serve until the 2029 Annual Meeting. They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the 2026 fiscal year and approved an adjournment proposal, although an adjournment was not needed.